Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 10:09 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1969–1992 of 16,135 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Skin Disorder Clear all

Conditions: Psoriasis, Atopic Dermatitis
Interventions: XmAb27564, Placebo; Biological
Lead sponsor: Xencor, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 6
States / cities: Sherman Oaks, California • Thousand Oaks, California • Coral Gables, Florida + 3 more

Conditions: Melanoma (Skin), Metastatic Cancer
Interventions: temozolomide, radiation therapy; Drug · Radiation
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 45
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Beech Grove, Indiana + 24 more

Conditions: Port Wine Stain
Interventions: Laser and rapamycin versus laser alone; Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 13 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Irvine, California

Conditions: Lupus Nephritis
Interventions: Anifrolumab, Placebo; Biological · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 17
States / cities: Glendale, Arizona • Phoenix, Arizona • La Jolla, California + 13 more

Conditions: Gastric Cancer, Invasive Breast Cancer, in Situ Breast Cancer, Mantle Cell Lymphoma, Larynx Cancer, Bladder Cancer
Interventions: Viewray MRIdian® Linac; Radiation
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Lupus Nephritis
Interventions: Atacicept, Mycophenolate mofetil, Placebo, Corticosteroids; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 16 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 12
States / cities: New Orleans, Louisiana • Shreveport, Louisiana • Detroit, Michigan + 9 more

Conditions: Necrotizing Fasciitis
Interventions: Acellular Fish Skin Graft (AFS) with Standard of Care Negative Pressure Wound Therapy (NPWT), Acellular Human Cadaver (AHC) with Standard of care Negative Pressure Wound Therapy (NPWT); Device · Other
Lead sponsor: Kerecis Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Chemotherapy-induced Nausea and Vomiting
Interventions: Fosaprepitant; Drug
Lead sponsor: St. Louis University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Venous Insufficiency, Leg Ulcer
Interventions: Bilayered Cellular Matrix (OrCel); Device
Lead sponsor: Ortec International; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 10
States / cities: Montgomery, Alabama • Phoenix, Arizona • Castro Valley, California + 7 more

Conditions: Dyskeratosis Congenita, Telomere Disease
Interventions: Quercetin; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 2 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Breast Cancer
Interventions: Aerobic Training, Educational Information, Supervised Home Based Training; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years to 80 Years · Female only
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Marfan Syndrome
Interventions: Atenolol, Losartan; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 25 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Carcinoma
Interventions: IM@Home Program, Medical Device Usage and Evaluation, Questionnaire Administration, Interview; Behavioral · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Seattle, Washington • Spokane Valley, Washington

Conditions: Marfan Syndrome, Turner Syndrome, Ehlers-Danlos Syndrome, Loeys-Dietz Syndrome, FBN1, TGFBR1, TGFBR2, ACTA2 or MYH11 Genetic Mutation, Bicuspid Aortic Valve Without Known Family History, Bicuspid Aortic Valve With Family History, Bicuspid Aortic Valve With Coarctation, Familial Thoracic Aortic Aneurysm and Dissections, Shprintzen-Goldberg Syndrome, Other Aneur/Diss of Thoracic Aorta Not Due to Trauma, <50yo, Other Congenital Heart Disease
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 3,706 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2016
U.S. locations: 7
States / cities: Honolulu, Hawaii • Baltimore, Maryland • New York, New York + 3 more

Conditions: Systemic Lupus Erythematosus
Interventions: AMG 570, AMG 570 Matching Placebo; Biological
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 3
States / cities: Evansville, Indiana • Overland Park, Kansas • Madison, Wisconsin

Conditions: Breast Cancer, Stage IV Breast Cancer
Interventions: palliative surgery, therapeutic conventional surgery, palliative radiation therapy, radiation therapy; Procedure · Radiation
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 120 Years
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 369
States / cities: Mobile, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 267 more

Conditions: Systemic Lupus Erythematosus
Interventions: Prasterone (GL701); Drug
Lead sponsor: Genelabs Technologies; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 21
States / cities: Tucson, Arizona • Los Angeles, California • Rancho Mirage, California + 18 more

Conditions: Breast Cancer
Interventions: Cognitive behavioral therapy CBT) for weight loss; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 90 Years · Female only
Enrollment: 253 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Mucopolysaccharidosis II
Interventions: Observational; Other
Lead sponsor: REGENXBIO Inc.; Industry
Eligibility: 1 Month to 8 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Oakland, California • Philadelphia, Pennsylvania

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Applied Spectral Imaging Ltd.; Industry
Eligibility: 21 Years and older · Female only
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 2
States / cities: Lakewood, New Jersey • Temple, Texas

Conditions: Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, Psoriatic Arthritis
Interventions: Bimekizumab, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 435 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 20
States / cities: San Diego, California • Santa Monica, California • Fort Myers, Florida + 15 more

Conditions: Breast Carcinoma, Carcinoma of Unknown Primary, Endometrial Carcinoma, Esophageal Carcinoma, Liver Failure, Lung Carcinoma, Malignant Head and Neck Neoplasm, Malignant Testicular Neoplasm, Melanoma, Metastatic Malignant Solid Neoplasm, Ovarian Carcinoma, Renal Failure, Unresectable Malignant Neoplasm, Urothelial Carcinoma
Interventions: Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study, Veliparib; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2027
U.S. locations: 17
States / cities: Duarte, California • Sacramento, California • South Pasadena, California + 13 more

Conditions: Cardiotoxicity, Cancer, Cardiac Arrhythmia, Left Ventricular Dysfunction, Breast Cancer, Multiple Myeloma
Interventions: Mobile Cardiac Telemetry, Wearable Cardiac Monitor; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Metastatic Uveal Melanoma
Interventions: IDE196, Crizotinib, Pembrolizumab, Ipilimumab, Nivolumab, Dacarbazine; Drug
Lead sponsor: IDEAYA Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 31
States / cities: Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 23 more

Search by objective public record fields.

Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis

Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System

A Randomized Trial to Study Combined Pulsed Dye Laser and Rapamycin Treatment of Port Wine Stain Birthmarks.

Safety and Efficacy of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Proliferative Lupus Nephritis

CONFIRM: Magnetic Resonance Guided Radiation Therapy

The Efficacy and Safety of Atacicept in Combination With Mycophenolate Mofetil Used to Treat Lupus Nephritis

AFS Compared to AHC in Treatment of Necrotizing Fasciitis NF

Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma

The Evaluation of OrCel for the Treatment of Venous Ulcers

Quercetin Dyskeratosis Congenita (DC)/Telomere Biology Disorders (TBD)

Supervised Aerobic Training During or After Chemotherapy for Operable Breast Cancer

Effects of Losartan Versus Atenolol on Aortic and Cardiac Muscle Stiffness in Adults With Marfan Syndrome

A Digital Health Intervention to Improve Symptoms and Physical Activity During Breast Radiation

National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions

Single Ascending Dose Study of AMG 570 in Healthy Subjects

Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer

GL701 (Prestara™) in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids

Weight Reduction Intervention for Breast Cancer Survivors

Mucopolysaccharidosis Type II Observational

Detection of Amplification of Her2 Fluorescent in Situ Hybridization (FISH) in Breast Tissue Sections

A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

Monitoring for CardioToxicity Using WeArable deVices While Undergoing cancEr Treatments (MCT-WAVE)

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma